In Hooykaas’ work, they showed that miR-BART16 targeted the key transcriptional co-activator cAMP response element-binding protein (CBP) in the IFN signaling transduction, resulting in the downregulation of CBP in the tumor cells and ultimately suppressed the anti-proliferative effect of IFN-α (59). The gene discussed is IFNA1; the disease is neoplasm.